373 related articles for article (PubMed ID: 28980866)
1. GSK3β-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells.
Liu SL; Liu Z; Zhang LD; Zhu HQ; Guo JH; Zhao M; Wu YL; Liu F; Gao FH
Cell Cycle; 2017; 16(24):2386-2395. PubMed ID: 28980866
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
3. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin induces G
Chen MJ; Cheng AC; Lee MF; Hsu YC
J Cell Physiol; 2018 Jun; 233(6):4618-4625. PubMed ID: 28833099
[TBL] [Abstract][Full Text] [Related]
5. Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.
Hong M; Almutairi MM; Li S; Li J
Phytomedicine; 2020 Mar; 68():153174. PubMed ID: 31991293
[TBL] [Abstract][Full Text] [Related]
6. Metformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer.
Gwak H; Kim Y; An H; Dhanasekaran DN; Song YS
Mol Carcinog; 2017 Feb; 56(2):349-358. PubMed ID: 27128966
[TBL] [Abstract][Full Text] [Related]
7. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
8. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
9. [β-Lapachone combined with NVP-BEZ235 inhibit proliferation and migration of BGC-823 gastric cancer cells].
Cui X; Chen L; Sun J; Wang Y; Lin Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Feb; 34(2):129-135. PubMed ID: 29673455
[TBL] [Abstract][Full Text] [Related]
10. The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
Xu CX; Li Y; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
PLoS One; 2011; 6(6):e20899. PubMed ID: 21695126
[TBL] [Abstract][Full Text] [Related]
11. Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/ GSK3β/cyclin D1 pathway.
Wang J; Li XM; Bai Z; Chi BX; Wei Y; Chen X
J Ethnopharmacol; 2018 Jan; 210():1-9. PubMed ID: 28684297
[TBL] [Abstract][Full Text] [Related]
12. Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.
Li J; Wang X; Ma C; Xu S; Xu M; Yang J; Wang R; Xue L
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 34223631
[TBL] [Abstract][Full Text] [Related]
13. NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation.
Ruan B; Liu W; Chen P; Cui R; Li Y; Ji M; Hou P; Yang Q
Int J Biol Sci; 2020; 16(4):682-693. PubMed ID: 32025215
[TBL] [Abstract][Full Text] [Related]
14. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells.
Masamha CP; Benbrook DM
Cancer Res; 2009 Aug; 69(16):6565-72. PubMed ID: 19638577
[TBL] [Abstract][Full Text] [Related]
16. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
17. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability
Yuan Y; Fan Y; Gao Z; Sun X; Zhang H; Wang Z; Cui Y; Song W; Wang Z; Zhang F; Niu R
Cancer Biol Med; 2020 Aug; 17(3):707-725. PubMed ID: 32944401
[No Abstract] [Full Text] [Related]
18. Inhibition of Rac1 activity induces G1/S phase arrest through the GSK3/cyclin D1 pathway in human cancer cells.
Liu L; Zhang H; Shi L; Zhang W; Yuan J; Chen X; Liu J; Zhang Y; Wang Z
Oncol Rep; 2014 Oct; 32(4):1395-400. PubMed ID: 25109327
[TBL] [Abstract][Full Text] [Related]
19. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
[TBL] [Abstract][Full Text] [Related]
20. Synergistic anti-proliferative and apoptotic effect of NVP-BEZ235 and curcumin on human SH-SY5Y neuroblastoma cells.
Çetin F; Kosba S; Abdik H; Bolat ZB
Med Oncol; 2023 Dec; 41(1):11. PubMed ID: 38071672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
